Artivion, formerly known as CryoLife, Inc., is based in Kennesaw, Georgia, and focuses on the development and commercialization of medical devices. The company has demonstrated strong revenue growth of 13% in the last twelve months, and analysts maintain a bullish outlook with price targets ranging from $32 to $35. For deeper insights into Artivion's financials and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro. The company has demonstrated strong revenue growth of 13% in the last twelve months, and analysts maintain a bullish outlook with price targets ranging from $32 to $35. For deeper insights into Artivion's financials and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro.
Artivion, formerly known as CryoLife, Inc., is based in Kennesaw, Georgia, and focuses on the development and commercialization of medical devices. The company has demonstrated strong revenue growth of 13% in the last twelve months, and analysts maintain a bullish outlook with price targets ranging from $32 to $35. For deeper insights into Artivion's financials and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro.
Artivion, formerly known as CryoLife, Inc., is based in Kennesaw, Georgia, and focuses on the development and commercialization of medical devices.
In other recent news, Artivion, Inc. has been granted an FDA exemption for its new aortic dissection device, a promising development for the medical device company. The AMDS, recognized as the first of its kind in treating acute DeBakey Type I aortic dissections, has shown significant reductions in major adverse events compared to the standard care. Artivion's CEO, Pat Mackin, has expressed the company's commitment to making the device accessible to U.S. facilities and physicians.
Artivion has also reported a cybersecurity incident, although it does not anticipate a material impact from this event. The company continues to exhibit a solid financial performance, with a 10% year-over-year increase in revenue to $95.8 million in Q3 2024 and a 28% rise in adjusted EBITDA to $17.7 million. For the full year, Artivion anticipates a revenue growth of 10% to 12%, with projected revenues between $389 million and $396 million.
Artivion has also made progress in regulatory milestones, including the filing of the first module of the AMDS PMA and NMPA approval for BioGlue in China. Analysts have discussed a $20 million opportunity related to BioGlue in China, with significant progress expected in H2 2025. These recent developments suggest a solid growth trajectory for Artivion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.